JSPR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
9.2M
-15.9%
11.0M
-30.9%
15.8M
-17.4%
19.2M
-29.2%
27.1M
R&D
5.1M
-11.7%
5.8M
-48.8%
11.4M
-21.1%
14.4M
-32.1%
21.2M
SG&A
4.1M
-20.7%
5.1M
+14.7%
4.5M
-6.2%
4.8M
-18.8%
5.9M
Operating Income
-9207000
+15.9%
-10952000
+30.9%
-15839000
+17.4%
-19166000
+29.2%
-27076000
EBITDA
-9186000
+16.0%
-10931000
+29.7%
-15549000
+17.9%
-18937000
+29.4%
-26818000
Net Income
-2760000
-135.1%
-1174000
+87.1%
-9101000
+51.4%
-18736000
+29.9%
-26723000
EPS (Basic)
$-0.10
-150.0%
$-0.04
+87.1%
$-0.31
+72.6%
$-1.13
+35.1%
$-1.74
EPS (Diluted)
$-0.10
-150.0%
$-0.04
+87.1%
$-0.31
+72.6%
$-1.13
+35.1%
$-1.74
Shares (Diluted)
28.7M
+0.1%
28.7M
-3.4%
29.7M
+78.4%
16.6M
+8.5%
15.3M
Jasper Therapeutics (JSPR) โ€” Financials